Patient Scenario 2: JAK2 Inhibitors in Myelofibrosis
After reviewing the second patient scenario of myelofibrosis, experts from the John Theurer Cancer Center discuss the use of JAK inhibitors, specifically ruxolitinib, to manage patients in the frontline setting.
Read More
Momelotinib’s Role in the Myelofibrosis Treatment Paradigm
Key opinion leaders on myelofibrosis management consider the potential role of momelotinib within the current treatment paradigm.
Read More
Pacritinib in Myelofibrosis: Adverse Event Management and Dosing
Shared insight on the safety profile of pacritinib and how best to mitigate or manage adverse events when they occur in patients with myelofibrosis.
Read More
Myelofibrosis: Potential Impact of Pacritinib on Anemia
Experts continue their conversation on pacritinib in myelofibrosis by reviewing its potential impact on anemia and ACVR1.
Read More
Clinical Data With Pacritinib in Patients With Myelofibrosis
Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.
Read More
Evolving Treatment Armamentarium for Myelofibrosis
Key opinion leaders provide a broad perspective on the current treatment armamentarium available to patients diagnosed with myelofibrosis.
Read More
Optimizing MF Management With Multidisciplinary Care
A comprehensive discussion on the members of a healthcare team who might help to diagnose and manage a patient with myelofibrosis.
Read More
Patient Scenario 1: Diagnosis and Risk Stratification of MF
After reviewing the first patient scenario of myelofibrosis, experts from the John Theurer Cancer Center reflect on best practices in diagnosing and risk stratifying patients.
Read More
Sequencing Therapies in Relapsed/Refractory ALL
Ibrahim Aldoss, MD, and James K. McCloskey, MD, share thoughts on how to effectively sequence available treatment modalities for acute lymphocytic leukemia in various patient populations.
Read More
Salvage Therapies in R/R ALL, Including CAR T-Cell Therapy
Drs Aldoss and McKloskey describe treatments that can be used in the salvage setting of acute lymphocytic leukemia, including CAR T-cell therapy.
Read More
Approaches to Treatment for Relapsed/Refractory ALL
Ibrahim Aldoss, MD and James K. McCloskey, MD describe treatment modalities that can be utilized in treating a pediatric or AYA patient with relapsed / refractory ALL.
Read More
Approaches to Treatment After Failure to Achieve MRD Negativity
Insights on how to approach an acute lymphocytic leukemia patient who is MRD positive after induction therapy.
Read More
Choosing a Treatment Setting for Patients With ALL
Drs Aldoss and McCloskey share their thoughts on treating patients with ALL at community centers versus at tertiary, academic medical centers.
Read More
Approaches to Treatment of Ph- ALL
Ibrahim Aldoss, MD; and James K. McCloskey, MD, discuss how to approach the treatment of a pediatric or AYA patient with ALL who is Philadelphia chromosome-negative (Ph-).
Read More
Approaches to Treatment of Ph+ ALL
A discussion on how to approach the treatment of a pediatric or AYA (adolescent and young adult) patient with ALL (acute lymphoblastic leukemia) who is Philadelphia chromosome positive (Ph+ALL).
Read More
Ibrahim Aldoss, MD, and James K. McCloskey, MD, share their thoughts on different stratification measures used to assess risk in pediatric, adolescent, and young adult patients newly diagnosed with ALL.
Read More